Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Quidel, Hologic, and Quest Diagnostics Shares Fell Today

By Brian Orelli, PhD – Updated Aug 27, 2020 at 3:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Rival Abbott is looking to become the dominant player in the coronavirus test arena.

What happened

Shares of Quidel (QDEL) were down a whopping 27% at 2:27 p.m. EDT on Thursday after rival Abbott Laboratories (ABT -1.56%) gained emergency use authorization from the Food and Drug Administration for its 15-minute, $5 test for the novel coronavirus. Fellow test makers Hologic (HOLX -0.74%) and Quest Diagnostics (DGX -1.55%) were down 6% and 7%, respectively.

So what

Quidel fell the most because its COVID-19 test, the Sofia SARS Antigen FIA, is in the same class as Abbott's BinaxNOW COVID-19 Ag Card test. Both are so-called antigen tests that detect the coronavirus by looking for the viral proteins rather than genetic material from the coronavirus, which molecular tests detect.

The advantage of testing for proteins versus genetic material is that the latter generally has to be amplified, which takes time and requires a machine to run the molecular amplification steps.

Quidel's test can also generate results in 15 minutes, rivaling Abbott's test, but it requires the testing location to own one of Quidel's Sofia instruments, which can run tests for a wide range of diseases from strep throat to the flu. Abbott's test, on the other hand, is a stand-alone product capable of giving a readout without a separate device..

The FDA has authorized 181 molecular tests, but Abbott's test was only the fourth antigen test to be given an emergency use authorization. In addition to Abbott and Quidel, privately held LumiraDx has a test, as does Becton, Dickinson (BDX -1.46%). The latter's stock was down a modest 3% today, which seems reasonable given that it's a substantially diversified healthcare company with a $71 billion market cap.

Neither Hologic nor Quest has an antigen test, but their FDA authorized molecular tests (Hologic has two and Quest has four) will compete directly with Abbott's BinaxNOW COVID-19 Ag Card test.

Hand taking a nasal swab

Image source: Getty Images.

Now what

While competition is rarely good for any company, Abbott's test may end up substantially expanding the COVID-19 testing market rather than directly taking market share from Quidel, Hologic, and Quest. Testing in the U.S. has certainly been supply-constrained over the last few weeks with reports of patients receiving results weeks after being given the test.

Abbott is also promoting its test as helping to "facilitate return to daily activities." The test will be linked to a new mobile app that patients can use to prove they're not infected with the coronavirus. If the U.S. is at the point where it's testing a lot of asymptomatic people just to make sure they're not positive, the testing market will naturally have to be substantially larger than it is currently.

Even if Abbott cuts into the market share of Quidel, Hologic, and Quest, the three companies are well diversified and should come out of the pandemic ready to get back to promoting the rest of their offerings.

Quidel, for example, should benefit greatly from the increased placements of Sofia instruments, which doctors' offices have been buying primarily so they can offer in-house COVID-19 tests. There were about 50,000 Sofia analyzers installed as of the company's earnings report at the end of July, with the company able to manufacture 2,500 machines per month, which could increase to 7,500 to 10,000 instruments by September. Once the pandemic is over, the company can promote all the other tests that can be run on the Sofia machines, generating recurring revenue that wasn't available previously.

Hologic is in a similar situation. Its COVID-19 molecular tests run on its Panther systems, which can test for other infectious diseases as well. In the most recently completed quarter, the company placed 208 Panther systems, quite a feat considering it was averaging 228 system placements per year over the last several years.

Finally Quest is arguably more diversified than either of the other companies, offering a wide range of diagnostic tests that are routinely ordered by doctors. The company may not experience a post-pandemic boost from new customers, but it should eventually see increased revenue from all the tests that patients have put off as they've avoided doctors' offices during the pandemic.

Brian Orelli, PhD has no position in any of the stocks mentioned. The Motley Fool recommends Becton, Dickinson and Quidel. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Hologic, Inc. Stock Quote
Hologic, Inc.
$64.52 (-0.74%) $0.48
Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
$122.69 (-1.55%) $-1.93
Quidel Corporation Stock Quote
Quidel Corporation
Abbott Laboratories Stock Quote
Abbott Laboratories
$96.76 (-1.56%) $-1.53
Becton, Dickinson and Company Stock Quote
Becton, Dickinson and Company
$222.83 (-1.46%) $-3.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.